Drug combos may prove more costly than generic components, study finds

Branded fixed-dose combinations could be costing Medicare nearly $1 billion a year compared to buying the component generic drugs separately, according to a study by researchers from Brigham and Women's Hospital and Harvard Medical School published Tuesday by JAMA.